Effect of different dox concentration with hapten and dose selection intratumoral injection on the survival time of tumor bearing mice.

e15517 Background: To explore the effect of chemotherapeutic drug (Dox) with the concentration on the survival of tumor-bearing mice after intratumoral injection plus hapten. It is important to observe whether there is any difference in survival rate between the different dose of drug-administered group with hapten and the positive control group. Methods: The H22 liver tumor-bearing mice with the longest path length of tumors of 5-8 mm were selected and administered according to the tumor volume. The second dose was administered at intervals of 7 days. The death of the mice was observed daily and the time of death was recorded in order to evaluate the survival of the mice. Results: The effect on body weight, except for the negative control group, decreased in weight after the first administration, and the effect was reversible. The effect on tumor volume was significantly slower than that of the negative control group after administration. In the life extension rate study, the sustained-release drug group was compared with the corresponding positive control group, the sustained-release drug group II and the positive control group II, the sustained-release drug group IV group and the positive control group IV group, and the sustained-release drug group V and The positive control group V had significant significance (P < 0.01). Therefore, the survival time of the group IV of the sustained-release drug was better than that of the positive control group IV, and the dose of the group IV of the sustained-release drug was the optimal dose. Conclusions: The reduction of doxorubicin hydrochloride concentration can prolong the survival time of mice and the survival rate of the sustained-release drug group with hapten is generally higher than that of the positive control group. By comparing the tumor inhibition rate and survival test results of the slow release drug group with hapten and the positive control group, the concentration of doxorubicin hydrochloride was initially screened at 1.0 mg/ml which is best concentration for this therapy.